Monday December 11, 2017 Omalizumab Improves Efficacy of Oral Immunotherapy for Multiple Food Allergies Combining a 16-week initial course of omalizumab with oral immunotherapy (OIT) greatly improves the efficacy of OIT for children with allergies to multiple foods, results from a NIAID-funded clinical trial show. After 36 weeks, more than 80 percent of children who received omalizumab and OIT could safely consume two-gram portions of at least two foods to which they were allergic, compared with only a third of children who received placebo and OIT.  The findings suggest the potential benefits of using omalizumab to safely and rapidly facilitate desensitization to multiple food allergens. Additional, larger studies will be needed to confirm and expand on these promising results. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107

Tweet

Postingan terkait:

— Monday, December 11, 2017 — Add Comment